Inhibitors of HMG-CoA reductase (or “statins”) catalyze the conversion of hydroxymethylglutaryl-CoA to mevalonate and are widely used for treatment of hyperlipidemia. This evidence concerns the gene HMGCR and hyperlipidemia.